HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that the Phase I study for PLX-PAD in critical limb ischemia (CLI) will be presented at the MSC2009 Regenerative Medicine and Adult Stem Cell Therapy conference.
